Outcomes of Multimodality Breast Screening for Women at Increased Risk of Familial Breast Cancer

被引:7
作者
Bennett, Ian C. [1 ]
Muller, Jennifer [2 ]
Cockburn, Linda
Joshua, Helen
Thorley, Gillian [3 ]
Baker, Christine
Wood, Nili
Brazier, Jane
Jones, Mark [4 ]
Dunn, Nathan [5 ]
Gattas, Michael [6 ]
机构
[1] Univ Queensland, Dept Surg, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[2] Queensland Hlth, Canc Screening Serv, Brisbane, Qld, Australia
[3] BreastScreen Queensland, N Brisbane Serv, Familial Breast Canc Screening Clin, Brisbane, Qld, Australia
[4] Univ Queensland, Princess Alexandra Hosp, Sch Populat Hlth, Brisbane, Qld, Australia
[5] Queensland Hlth, BreastScreen Queensland, Monitoring, Brisbane, Qld, Australia
[6] Royal Brisbane Hosp, Queensland Clin Genet Serv, Brisbane, Qld 4006, Australia
关键词
BRCA2 MUTATION CARRIERS; MAMMOGRAPHY; HISTORY; SURVEILLANCE; SONOGRAPHY; MANAGEMENT; EFFICACY; GENE; SUSCEPTIBILITY; ULTRASOUND;
D O I
10.1007/s00268-010-0409-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
While population-based breast screening for women over the age of 50 years is a generally accepted and proven health strategy, the role of breast screening specifically among women at high risk of familial breast cancer has remained controversial. Indeed, there are very few services specifically offering a breast-screening program for women at high risk of familial breast cancer. In 1999 a Familial Breast Cancer Screening Clinic (FBCSC) was established at the North Brisbane BreastScreen Queensland Service to provide a regular multimodality screening program utilizing clinical breast examination, breast ultrasound, and mammography for women at higher risk of hereditary breast cancer and with entry into the program commencing from the age of 30 years. Since its inception, a total of 2440 women have participated in the FBCSC. A total 7051 breast-screening examinations have been performed on these participants, with 53 breast cancers being diagnosed, including 8 in situ ductal carcinomas, 38 invasive ductal carcinomas, and 7 invasive lobular carcinomas. The mean size of the cancers was 16 mm (range = 1-45 mm), and of the 45 invasive cancers, 60% were less than or equal to 15 mm in size. The overall axillary node positive rate was 24.5% (13/53). The invasive cancer detection rate for first-round screening was 8.3 cancers per 1000 women screened, with 5.2 cancers per 1000 women detected on subsequent round screening. The results from this service demonstrate that multimodality screening for women at high risk of familial breast cancer and including women of younger age is effective and appropriate, with very acceptable cancer detection rates and pathological cancer characteristics being observed consistent with early-stage detection. The colocated siting of this service within a BreastScreen Queensland facility has proven to be efficient and cost effective.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 48 条
[1]  
Anderson J, 2004, BREAST CANCER RES TR, V88, pS188
[2]   The BOADICEA model of genetic susceptibility to breast and ovarian cancer [J].
Antoniou, AC ;
Pharoah, PPD ;
Smith, P ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1580-1590
[3]   The management of familial breast cancer [J].
Bennett, IC ;
Gattas, M ;
Teh, BT .
BREAST, 2000, 9 (05) :247-263
[4]   Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [J].
Berry, DA ;
Parmigiani, G ;
Sanchez, J ;
Schildkraut, J ;
Winer, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :227-238
[5]  
BreastScreen Australia National Accreditation Standards, 2004, DEV NAT QUAL MAN COM
[6]   Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk [J].
Brekelmans, CTM ;
Seynaeve, C ;
Bartels, CCM ;
Tilanus-Linthorst, MMA ;
Meijers-Heijboer, EJ ;
Crepin, CMG ;
van Geel, AN ;
Menke, M ;
Verhoog, LC ;
van den Ouweland, A ;
Obdeijn, IM ;
Klijn, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :924-930
[7]  
Chart PL, 1997, CAN MED ASSOC J, V157, P1235
[8]  
Ciatto S, 1994, Radiol Med, V88, P221
[9]  
CLAUS EB, 1991, AM J HUM GENET, V48, P232
[10]  
CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO